Literature DB >> 34559375

Stress load and neurodegeneration after gastrostomy tube placement in amyotrophic lateral sclerosis patients.

L Brylev1,2,3,4, V Fominykh5,6, V Chernenkaia1, I Chernenkiy7, K Gorbachev1, A Ataulina1, A Izvekov8, M Monakhov1, A Olenichev1, S Orlov1, I Turin9, M Loginov1, S Rautbart1, A Baymukanov1, V Parshikov4, V Demeshonok4, A Yakovlev2,3, T Druzhkova3, A Guekht3,10, N Gulyaeva2,3.   

Abstract

Dysphagia and progressive swallowing problems due to motoneuron death is one of amyotrophic lateral sclerosis (ALS) symptoms. Malnutrition and body weight loss result in immunological disturbances, fatigability and increase risk of secondary complications in ALS patients, percutaneous endoscopic gastrostomy tube (PEG) placement representing a well-recognized method for malnutrition correction and potentially increasing life expectancy. However, despite nutritional correction, occasional rapid neurological deterioration may develop after PEG placement. We have hypothesized that this decline can be a result of exteroceptive stress during PEG placement and promote neurodegeneration in ALS patients. Intravenous sedation may decrease stress during invasive procedures and it is safe during PEG placement in ALS patients. The aim of the study was comparing different PEG placement protocols of anesthesia (local anesthesia or local anesthesia plus intravenous sedation) in ALS from perspectives of stress load and neurological deterioration profile. During 1.5 years 94 ALS patients were admitted; gastrostomy was performed in 79 patients. After screening according to inclusion and exclusion criteria, 30 patients were included in the prospective consecutive study. All patients were divided in two groups, with local anesthesia and with combination of local anesthesia and intravenous sedation. Routine biochemical indices, neurodegeneration and stress markers were measured. The age of ALS patients was 61 ± 10 years; 20 patients were included at stage 4A and 10 at stage 4B (King's College staging). PEG was placed at average14 months after the diagnosis and 2.2 years after first symptoms. Mean ALS Functional Rating Scale-Revised was 27.8, mean forced vital capacity of lung 46.3% (19-91%). After one year of observation only 8 patients survived. Mean life duration after PEG was 5 months (5 days-20 months). Comparison of two PEG placement protocols did not reveal differences in survival time, stress load and inflammation level. Higher saliva cortisol levels, serum cortisol, glucose, C-reactive protein and interleukin-6 were detected after PEG placement, confirming considerable stress response. PEG is a stressful factor for ALS patients, PEG placement representing a natural model of exteroceptive stress. Stress response was detected as increased cortisol, C-reactive protein, interleukin-6, and glucose levels. Intravenous sedation did not increase the risk of PEG placement procedure, however, sedation protocol did not affect stress load.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  ALS; Gastrostomy; Neurodegeneration; Neuroinflammation; Sedation; Stress

Mesh:

Year:  2021        PMID: 34559375     DOI: 10.1007/s11011-021-00837-x

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  17 in total

Review 1.  Nutritional management in MND/ALS patients: an evidence based review.

Authors:  Catherine Heffernan; Crispin Jenkinson; Tricia Holmes; Gene Feder; Richard Kupfer; P Nigel Leigh; Sue McGowan; Alan Rio; Paul Sidhu
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2004-06

2.  Salivary cortisol determinations and self-rating scales in the assessment of stress in patients undergoing the extraction of wisdom teeth.

Authors:  C M Hill; R V Walker
Journal:  Br Dent J       Date:  2001-11-10       Impact factor: 1.626

Review 3.  Amyotrophic lateral sclerosis and anesthesia: a case series and review of the literature.

Authors:  Alan M Hoeper; David W Barbara; James C Watson; Juraj Sprung; Toby N Weingarten
Journal:  J Anesth       Date:  2019-01-17       Impact factor: 2.078

4.  Takotsubo cardiomyopathy in amyotrophic lateral sclerosis.

Authors:  Seok-Jin Choi; Yoon-Ho Hong; Je-Young Shin; Byung-Nam Yoon; Sung-Yeon Sohn; Chan Soon Park; Jung-Joon Sung
Journal:  J Neurol Sci       Date:  2017-02-08       Impact factor: 3.181

Review 5.  CNS disease triggering Takotsubo stress cardiomyopathy.

Authors:  Josef Finsterer; Karim Wahbi
Journal:  Int J Cardiol       Date:  2014-08-26       Impact factor: 4.164

6.  Biochemical parameters in determination of nutritional status in amyotrophic lateral sclerosis.

Authors:  Beata Chełstowska; Magdalena Kuźma-Kozakiewicz
Journal:  Neurol Sci       Date:  2020-01-02       Impact factor: 3.307

7.  Coping strategies in anxious surgical patients.

Authors:  Hansjoerg Aust; Dirk Rüsch; Maike Schuster; Theresa Sturm; Felix Brehm; Yvonne Nestoriuc
Journal:  BMC Health Serv Res       Date:  2016-07-12       Impact factor: 2.655

8.  Interleukin-6, S-Nitrosothiols, and Neurodegeneration in Different Central Nervous System Demyelinating Disorders: Is There a Relationship?

Authors:  Vera Fominykh; Anna Vorobyeva; Mikhail V Onufriev; Lev Brylev; Maria N Zakharova; Natalia V Gulyaeva
Journal:  J Clin Neurol       Date:  2018-05-31       Impact factor: 3.077

9.  Lipidomics Reveals Cerebrospinal-Fluid Signatures of ALS.

Authors:  H Blasco; C Veyrat-Durebex; C Bocca; F Patin; P Vourc'h; J Kouassi Nzoughet; G Lenaers; C R Andres; G Simard; P Corcia; P Reynier
Journal:  Sci Rep       Date:  2017-12-15       Impact factor: 4.379

10.  ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS.

Authors:  Christopher Crockford; Judith Newton; Katie Lonergan; Theresa Chiwera; Tom Booth; Siddharthan Chandran; Shuna Colville; Mark Heverin; Iain Mays; Suvankar Pal; Niall Pender; Marta Pinto-Grau; Ratko Radakovic; Christopher E Shaw; Laura Stephenson; Robert Swingler; Alice Vajda; Ammar Al-Chalabi; Orla Hardiman; Sharon Abrahams
Journal:  Neurology       Date:  2018-09-12       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.